Navigation Links
Therapeutic cloning gets a boost with new research findings
Date:3/24/2009

San Antonio Germ cells, the cells which give rise to a mammal's sperm or eggs, exhibit a five to ten-fold lower rate of spontaneous point mutations than adult somatic cells, which give rise to the body's remaining cell types, tissues and organs. Despite their comparatively higher mutation rates, however, adult somatic cells are used as the donor cells in a cloning process called somatic cell nuclear transfer (SCNT). This made researchers wonder if cloning by SCNT leads to progeny with more mutations than their naturally conceived counterparts. Also, would cloned fetuses receive DNA programming predisposing them to develop mutations faster than natural fetuses of the same age?

Those scenarios are simply not likely, say researchers at The University of Texas at San Antonio, The University of Texas Health Science Center at San Antonio and The University of Hawaii at Honolulu's John A. Burns School of Medicine. The team, which spent more than five years analyzing mutation rates and types in cloned Big Blue mouse fetuses recently published its findings in the online Early Edition of the Proceedings of the National Academy of Sciences in a paper titled "Epigenetic regulation of genetic integrity is reprogrammed during cloning."

The paper offers the first direct demonstration that cloning does not lead to an increase in the frequency of point mutations.

John McCarrey, professor of cellular and molecular biology at UTSA and the study's principal investigator, suggests a "bottleneck effect" is partially responsible for the observations his team recorded. "To create a cloned fetus by somatic cell nuclear transfer, only one adult somatic cell -- one donor cell -- is needed," he explains. "Because a random cell population exhibits a low mutation rate overall and only one cell from that population is used for cloning, the likelihood is remote that the cell chosen to be cloned will transfer a genetic mutation to its cloned offspring.
'/>"/>

Contact: Christi Fish
christi.fish@utsa.edu
210-458-7584
University of Texas at San Antonio
Source:Eurekalert

Page: 1 2

Related biology news :

1. Therapeutic hypothermia is promising strategy to minimize tissue damage
2. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
3. Alzheimers disease therapeutic prevents long-term damage from TBI in pre-clinical studies
4. Magnetic nanoparticles navigate therapeutic genes through the body
5. New potential therapeutic target discovered for genetic disorder -- Barth syndrome
6. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
7. A novel target for therapeutics against Staph infection
8. Mitochondria could be a target for therapeutic strategy for Alzheimers disease patients
9. New therapeutic target identified for rheumatoid arthritis
10. Simple chemical procedure augments therapeutic potential of stem cells
11. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... E or a combination of the supplements had a similar ... supplements, according to data from a randomized controlled trial in ... the National Cancer Institute. Epidemiological studies have suggested ... and thus antioxidants, may have a lower risk of cancer. ...
... has the honour of becoming the first student from ... competition that pitted engineering students and young professionals from ... the Institution of Engineering and Technology (IET), UK, the ... Mechanical & Aerospace Engineering beat three other contestants in ...
... Is Sensitive to Irradiation Researchers led by ... irradiation damages fat tissue. They report their findings in ... of Pathology . Radiation therapy directed ... of tissues such as fat tissue has often been ...
Cached Biology News:Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial 2NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition 2NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition 3Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5
(Date:10/18/2014)... The Asian arthroscopic devices report defines and ... forecast of revenue. The arthroscopic devices market in Asia ... at a CAGR of 6.5% from 2013 to 2018. ... devices market, to get an idea of the in-depth ... segmentation of arthroscopic devices market in the same region, ...
(Date:10/18/2014)... October 18, 2014 The Asian Electronic Medical ... in Asian with analysis and forecast of revenue. The electronic ... grow to $2,328.0 million by 2018, at a CAGR of ... of the Asian Electronic Medical Record (EMR) market, to get ... a glimpse of the segmentation of the market in the ...
(Date:10/18/2014)... 2014 The report " Cloud ... Text; Web; Speech; Machine; Video; Predictive Analytics: Global ... Forecasts & Analysis (2013 - 2018) ", defines ... various sub segments with an in-depth analysis and ... the factors driving this market, various restraints, and ...
(Date:10/17/2014)... Alice,s journey through the looking-glass to Wonderland, mirrors in ... unexpected ways, including a new class of mirror that ... in The Optical Society,s (OSA) new high-impact journal ... first time, a new type of mirror that forgoes ... light by using an unusual magnetic property of a ...
Breaking Biology Technology:The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... Conference, SAN DIEGO, March 27 SGX Pharmaceuticals,(Nasdaq: ... the SGX523 clinical program., In January 2008, the ... SGX523 in patients with solid tumor cancers. The first,trial ... on a continuous,28-day cycle and the second trial has ...
... - GeneNews Limited (TSX: GEN),a company focused ... early,detection of diseases and personalized health management, ... fourth quarter and year ended,December 31, 2007., ... GeneNews because of the,advancements made for the ...
... Forms One of the Largest Sales Teams ... and PHILADELPHIA, March 26 /PRNewswire-FirstCall/,-- Shire plc ... company, announced today a co-promotion agreement with,TAP ... MMX(R),technology, indicated for the induction of remission ...
Cached Biology Technology:SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 2SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 3GeneNews announces 2007 year end results 2GeneNews announces 2007 year end results 3GeneNews announces 2007 year end results 4GeneNews announces 2007 year end results 5GeneNews announces 2007 year end results 6GeneNews announces 2007 year end results 7GeneNews announces 2007 year end results 8GeneNews announces 2007 year end results 9GeneNews announces 2007 year end results 10Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5
...
... is a type I eukaryotic topoisomerase that ... (also called right- and left-handed supercoils) from ... reaction is a covalently closed, circular DNA ... DNA Topoisomerase I does not absolutely require ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Biology Products: